Bendazac
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329308

CAS#: 20187-55-7

Description: Bendazac, also known as Bendazolic acid and AF-983, is an anticataract drug. It has been reported that Bendazac acts by preventing protein denaturation.


Price and Availability

Size
Price

200mg
USD 90
2g
USD 450
Size
Price

500mg
USD 150
5g
USD 750
Size
Price

1g
USD 250
10g
USD 1250

Bendazac, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329308
Name: Bendazac
CAS#: 20187-55-7
Chemical Formula: C16H14N2O3
Exact Mass: 282.1004
Molecular Weight: 282.299
Elemental Analysis: C, 68.08; H, 5.00; N, 9.92; O, 17.00


Synonym: Bendazac; AF 983; AF-983; AF983; Bendazolic acid; Bindazac; Versus

IUPAC/Chemical Name: 2-((1-benzyl-1H-indazol-3-yl)oxy)acetic acid

InChi Key: BYFMCKSPFYVMOU-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)

SMILES Code: O=C(O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Zhu P, Yang W, Hong L, Cheng Q, Luo L, He J, Chen J. Characterization of a novel process-related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR. J Pharm Biomed Anal. 2015 Mar 25;107:437-43. doi: 10.1016/j.jpba.2015.01.002. PubMed PMID: 25666544.

2: Yu JX, Yin XX, Shen JP, Qiu J, Yin HL, Jiang SJ. Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1231-8. PubMed PMID: 17184506.

3: Shen H, Gou S, Shen J, Zhu Y, Zhang Y, Chen X. Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2115-8. doi: 10.1016/j.bmcl.2010.02.061. PubMed PMID: 20223660.

4: Soldo L, Ruggieri A, Milanese C, Pinza M, Guglielmotti A. Bendazac lysine inhibition of human lens epithelial cell adhesion to polymethylmethacrylate intraocular lenses. Ophthalmic Res. 2004 May-Jun;36(3):145-50. PubMed PMID: 15103205.

5: Yin XX, Zhang YD, Shen JP, Wu HW, Zhu X, Li LM, Qiu J, Jiang SJ, Zheng XG. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. Acta Pharmacol Sin. 2005 Jun;26(6):721-8. PubMed PMID: 15916739.

6: Marques C, Ramalho JS, Pereira P, Mota MC. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol. 1995;90(4):395-404. PubMed PMID: 8620822.

7: Iwakiri K, Hata M, Miura Y, Numano K, Yuge M, Sasaki E. Allergic contact dermatitis due to bendazac and alclometasone dipropionate. Contact Dermatitis. 1999 Oct;41(4):218-39. Review. PubMed PMID: 10515101.

8: Guglielmotti A, Capezzone De Joannon A, Cazzolla N, Marchetti M, Soldo L, Cavallo G, Pinza M. Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. Pharmacol Res. 1995 Dec;32(6):369-73. PubMed PMID: 8736488.

9: Jez JM, Vanderkooi JM, Laties AM. Spectroscopic characterization of bendazac and benzydamine: possible photochemical modes of action. Biochem Biophys Res Commun. 1996 Apr 16;221(2):266-70. PubMed PMID: 8619844.

10: Alcalde M, Garcia-Diaz M, Najarro F, Donoso MS, Cebria L, Pascasio JM. Hepatotoxicity due to lysine salt of bendazac. Scand J Gastroenterol. 1996 Feb;31(2):206-8. PubMed PMID: 8658045.

11: Prieto de Paula JM, Rodríguez Rodríguez E, Villamandos Nicás V, Sanz de la Fuente H, Prada Mínguez A, del Portillo Rubí A. [Bendazac hepatotoxicity: analysis of 16 cases]. Rev Clin Esp. 1995 Jun;195(6):387-9. Spanish. PubMed PMID: 7644786.

12: Silva MP, Mira L, Lima J, Manso CF. Kinetics of the inhibition of xanthine dehydrogenase and of the reversible and irreversible forms of xanthine oxidase by silibinin and bendazac. Environ Toxicol Pharmacol. 1996 Jul 15;1(4):279-84. doi: 10.1016/1382-6689(96)00021-X. PubMed PMID: 21781693.

13: Nuzzi G, Venturini I, De Gregorio M, Arsenio L, Maraini G. Vitreous fluorophotometry and changes in blood-retinal barrier permeability induced by bendazac lysine. Acta Ophthalmol Scand. 1997 Feb;75(1):41-3. PubMed PMID: 9088399.

14: Chen XX, Zhang YD, Shen JP, Pu J, Yan HY, Zhu YQ, Qiu JJ. Pharmacokinetics of bendazac lysine in 10 Chinese young men. Zhongguo Yao Li Xue Bao. 1997 Mar;18(2):109-11. PubMed PMID: 10072958.

15: Romanelli L, Valeri P, Morrone LA, Pimpinella G, Graziani G, Tita B. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles. Life Sci. 1994;54(13):877-85. PubMed PMID: 8139376.